| |
original article |
Journal |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
Drug Metabolism and Disposition |
2024―Oct―29 |
Uncovering the Impact of COVID-19 Mediated Bidirectional Dysregulation of CYP3A4 on Systemic and Pulmonary Drug Concentrations Using Physiologically Based Pharmacokinetic Modeling |
Chukwunonso K. Nwabufo |
| 2 |
[GO] |
Journal of Pharmacology and Experimental Therapeutics |
2024―Aug―23 |
KVX-053, a Protein Tyrosine Phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 Spike protein subunit 1 - induced acute lung injury in mice |
Pavel A Solopov, Ruben Manuel Luciano Colunga Biancatelli, Tierney Day, Betsy Gregory, Elizabeth R Sharlow, John S. Lazo, John D Catravas |
| 3 |
[GO] |
Journal of Pharmacology and Experimental Therapeutics |
2024―Feb―09 |
Endothelial extracellular vesicles enriched in microRNA-34a predict new-onset diabetes in COVID-19 patients: novel insights for long-COVID metabolic sequelae |
Pasquale Mone, Stanislovas S. Jankauskas, Maria Virginia Manzi, Jessica Gambardella, Antonietta Coppola, Urna Kansakar, Raffaele Izzo, Giuseppe Fiorentino, Angela Lombardi, Fahimeh Varzideh, Daniela Sorriento, Bruno Trimarco, Gaetano Santulli |
| 4 |
[GO] |
Molecular Pharmacology |
2023―Oct―12 |
Targeting Cyclophilin A and CD147 to Inhibit Replication of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and SARS-CoV-2-Induced Inflammation |
Fan Yang, Chenglong Liu, Pengyuan Li, Aihua Wu, Yue Ma-Lauer, Hao Zhang, Zhuang Su, Wei Lu, Albrecht von Brunn, Di Zhu |
| 5 |
[GO] |
Drug Metabolism and Disposition |
2023―Sep―14 |
The Metabolism of Lufotrelvir, a Prodrug Investigated for the Treatment of SARS-COV2 in Humans Following Intravenous Administration |
Narayan Cheruvu, Esther van Duijn, Pieter A. Spigt, Ioana M. Barbu, Sima S. Toussi, Klaas Schildknegt, Rhys M. Jones, R. Scott Obach |
| 6 |
[GO] |
Journal of Pharmacology and Experimental Therapeutics |
2023―Apr―27 |
Modulation of the immune response to SARS-CoV-2 vaccination by NSAIDs |
Carsten Skarke, Ronan Lordan, Kayla Barekat, Amruta Naik, Divij Mathew, Takuya Ohtani, Allison R Greenplate, Gregory R Grant, Nicholas F Lahens, Sigrid Gouma, Elizabeth Troisi, Arjun Sengupta, Aalim M Weljie, Wenzhao Meng, Eline T Luning Prak, Kendall Lundgreen, Paul Bates, Hu Meng, Garret A. FitzGerald |
| 7 |
[GO] |
Drug Metabolism and Disposition |
2022―Oct―31 |
COVID-19 Vaccines and the Virus: Impact on Drug Metabolism and Pharmacokinetics |
Eliza R McColl, Maria A. Croyle, William C. Zamboni, William G Honer, Mark Heise, Micheline Piquette-Miller, Kerry B. Goralski |
| 8 |
[GO] |
Drug Metabolism and Disposition |
2022―Aug―30 |
The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro |
Yue Shen, William Eades, William Liu, Bingfang Yan |
| 9 |
[GO] |
Journal of Pharmacology and Experimental Therapeutics |
2022―Jul―03 |
Cardiovascular implications of miRNAs in COVID-19 |
Carmine Izzo, Valeria Visco, Jessica Gambardella, Germano Junior Ferruzzi, Antonella Rispoli, Maria Rosaria Rusciano, Anna Laura Toni, Nicola Virtuoso, Albino Carrizzo, Paola Di Pietro, Guido Iaccarino, Carmine Vecchione, Michele Ciccarelli |
| 10 |
[GO] |
Journal of Pharmacology and Experimental Therapeutics |
2022―Jun―30 |
Exosomal miR-145 and miR-885 regulate thrombosis in COVID-19 |
Jessica Gambardella, Urna Kansakar, Celestino Sardu, Vincenzo Messina, Stanislovas S. Jankauskas, Raffaele Marfella, Paolo Maggi, Xujun Wang, Pasquale Mone, Giuseppe Paolisso, Daniela Sorriento, Gaetano Santulli |
| 11 |
[GO] |
Journal of Pharmacology and Experimental Therapeutics |
2022―Mar―26 |
L-Arginine Enhances the Effects of Cardiac Rehabilitation on Physical Performance: New Insights for Managing Cardiovascular Patients During the COVID-19 Pandemic |
Pasquale Mone, Raffaele Izzo, Giuseppe Marazzi, Maria Virginia Manzi, Paola Gallo, Giuseppe Campolongo, Luca Cacciotti, Domenico Tartaglia, Giuseppe Caminiti, Fahimeh Varzideh, Gaetano Santulli, Valentina Trimarco |
| 12 |
[GO] |
Drug Metabolism and Disposition |
2022―Feb―13 |
Disposition of PF-07321332 (Nirmatrelvir), an Orally Bioavailable Inhibitor of SARS-CoV-2 3CL Protease, across Animals and Humans |
Heather Eng, Alyssa L Dantonio, Eugene P Kadar, R. Scott Obach, Li Di, Jian Lin, Nandini C. Patel, Britton Boras, Gregory S. Walker, Jonathan J. Novak, Emi Kimoto, Ravi Shankar P Singh, Amit S. Kalgutkar |
| 13 |
[GO] |
Molecular Pharmacology |
2022―Feb―01 |
A Comment on “Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites” |
Eric K. Johnson |
| 14 |
[GO] |
Molecular Pharmacology |
2022―Feb―01 |
Response to Comments on “Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites” |
Siennah R. Miller, Meghan E. McGrath, Kimberley M. Zorn, Sean Ekins, Stephen H. Wright, Nathan J. Cherrington |
| 15 |
[GO] |
Pharmacological Reviews |
2022―Jan―31 |
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines |
Simone Pecetta, Sven Kratochvil, Yu Kato, Kumaran Vadivelu, Rino Rappuoli, Qiang Ma |
| 16 |
[GO] |
Molecular Pharmacology |
2021―Sep―09 |
Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites |
Siennah R. Miller, Meghan E. McGrath, Kimberley M. Zorn, Sean Ekins, Stephen H. Wright, Nathan J. CHERRINGTON |
| 17 |
[GO] |
Journal of Pharmacology and Experimental Therapeutics |
2021―Jul―12 |
Cationic Compounds with SARS-CoV-2 Antiviral Activity and their Interaction with OCT/MATE Secretory Transporters. |
Lucy Jazmin Martinez Guerrero, Xiaohong Zhang, Kimberley M. Zorn, Sean Ekins, Stephen H. Wright |
| 18 |
[GO] |
Journal of Pharmacology and Experimental Therapeutics |
2021―May―10 |
Viral Proteases as Targets for COVID-19 Drug Development |
Wei Zhu, Zeenat A Shyr, Donald C. Lo, Wei Zheng |
| 19 |
[GO] |
Pharmacological Reviews |
2021―Mar―09 |
Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics |
Peter Garred, Andrea J. Tenner, Tom E. Mollnes, Finn Olav Levy |
| 20 |
[GO] |
Journal of Pharmacology and Experimental Therapeutics |
2021―Mar―05 |
COVID-19 drugs chloroquine and hydroxychloroquine, but not azithromycin and remdesivir, block hERG potassium channels |
Mark Szendrey, Jun Guo, Wentao Li, Tonghua Yang, Shetuan Zhang |
| 21 |
[GO] |
Journal of Pharmacology and Experimental Therapeutics |
2020―Oct―28 |
A Biomarker-Centric Approach to Drug Discovery and Development: Lessons Learned from the COVID-19 Pandemic |
Kelly A. Fader, Jiangwei Zhang, Joseph P. Menetski, Ravi I. Thadhani, Elliott M. Antman, Gary S. Friedman, Shashi K. Ramaiah, Vishal S. Vaidya |
| 22 |
[GO] |
Molecular Pharmacology |
2020―Oct―21 |
Dysregulation of ACE2 Expression and Function in Co-morbid Disease Conditions Possibly Contributes to COVID-19 Complication Severity |
Safaa Hammoud, Zena Wehbe, Samar Abdelhady, Firas Kobeissy, Ali Hussein Eid, Ahmed F El-Yazbi |
| 23 |
[GO] |
Journal of Pharmacology and Experimental Therapeutics |
2020―Oct―08 |
The Role of Smoking and Nicotine in the Transmission and Pathogenesis of COVID-19 |
Ali Ehsan Sifat, Saeideh Nozohouri, Heidi Villalba, Bhuvaneshwar Vaidya, Thomas J. Abbruscato |
| 24 |
[GO] |
Journal of Pharmacology and Experimental Therapeutics |
2020―Oct―02 |
Role of GILZ in the Kidney and the Cardiovascular System: Relevance to Cardiorenal Complications of COVID-19 |
Mahmood Mozaffari |
| 25 |
[GO] |
Molecular Pharmacology |
2020―Sep―10 |
Heparin-binding peptides as novel therapies to stop SARS-CoV-2 cellular entry and infection |
Omid Tavassoly, Farinaz Safavi, Iman Tavassoly |
| 26 |
[GO] |
Journal of Pharmacology and Experimental Therapeutics |
2020―Jul―29 |
Drug discovery strategies for SARS-CoV-2 |
Zeenat A Shyr, Kirill Gorshkov, Catherine Z Chen, Wei Zheng |
